The stock has climbed in the double-digits in recent years. Vertex Pharmaceuticals ( VRTX 1.53%) has proven itself to be an ...
Zacks Investment Research on MSN
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
Shares of Arcturus Therapeutics ARCT have plunged 59.4% in the past three months. The massive stock price drop was primarily ...
Purpose: Most cystic fibrosis mutation screening methods do not detect large exon deletions or duplications in the cystic fibrosis transmembrane regulator gene. We looked for such mutations in ...
Therapeutics Market Size accelerated to USD 10.60 billion in 2024, up from USD 9.22 billion in 2023, and is now projected to expand aggressively to USD 35.09 billion by 2033, recording a CAGR of 14.2% ...
Researchers have found in a new study that triple CFTR modulator therapy, or elexacaftor/tezacaftor/ivacaftor (ETI), produces ...
Please provide your email address to receive an email when new articles are posted on . Patients given aerosolized 4D-710 had elevated CFTR protein levels that went over normal levels. Over 12 months, ...
Vertex delivered strong performance across the board in Q3 with $3.08 billion in revenue, reflecting double-digit growth ...
Mutations in the cystic fibrosis trans membrane conductance regulator gene cause congenital bilateral absence of the vas deferens (CBAVD) in approximately 1% of the infertile males. It is a common ...
Cystic fibrosis is a life-limiting disease that is caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) protein activity. Phe508del is the most common CFTR ...
Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback